Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BridgeBio Pharma ( (BBIO) ) has issued an update.
BridgeBio Pharma held its Annual Meeting on June 20, 2025, where stockholders voted on several key proposals. These included the election of five Class III directors, approval of executive compensation, ratification of Deloitte & Touche LLP as the independent accounting firm, and amendments to the company’s stock option plan and certificate of incorporation. The meeting also approved the adjournment of the meeting if necessary due to insufficient votes.
The most recent analyst rating on (BBIO) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.
Spark’s Take on BBIO Stock
According to Spark, TipRanks’ AI Analyst, BBIO is a Neutral.
The overall stock score for BridgeBio Pharma reflects mixed factors. The earnings call provided a strong positive outlook due to the success of Attruby and pipeline advancements. However, significant financial risks and unattractive valuation metrics weigh heavily against the company. The technical analysis supports a positive short-term trend, but caution is warranted due to overbought conditions.
To see Spark’s full report on BBIO stock, click here.
More about BridgeBio Pharma
Average Trading Volume: 2,969,235
Technical Sentiment Signal: Buy
Current Market Cap: $7.92B
See more insights into BBIO stock on TipRanks’ Stock Analysis page.